Evidence map›Paper›PMID 37339111›Full record

ArticlePLOS global public health2023

Challenges of conducting an international observational study to assess immunogenicity of multiple COVID-19 vaccines.

Ratna Sardana, Placide Mbala Kingebeni, Wiwit Agung Snc, Abdoul H Beavogui, Jean-Luc Biampata, Djeneba Dabitao, Paola Del Carmen Guerra de Blas, Dehkontee Gayedyu-Dennis, Mory C Haidara, Ganbolor Jargalsaikhan and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 6 countries.

Ratna SardanaDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0002-5094-3942
Placide Mbala KingebeniInstitut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
Wiwit Agung SncRumah Sakit Umum Daerah Dr. H. Moch. Ansari Saleh Hospital, Banjarmasin, Indonesia.
Abdoul H BeavoguiCentre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, Guinea.
Jean-Luc BiampataInstitut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
Djeneba DabitaoUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.ORCID https://orcid.org/0000-0001-5150-6990
Paola Del Carmen Guerra de BlasThe Mexican Emerging Infectious Diseases Clinical Research Network, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-3050-6865
Dehkontee Gayedyu-DennisPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Mory C HaidaraCentre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, Guinea.
Ganbolor JargalsaikhanThe Liver Center, Onom Foundation, Ulan Bator, Mongolia.
Garmai NyuangarPartnership for Research on Vaccines and Infectious Diseases in Liberia, Monrovia, Liberia.
Asep PurnamaTC Hillers Hospital, Maumere, Indonesia.
Guillermo Ruiz PalaciosDepartamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID https://orcid.org/0000-0003-3708-9654
Seydou SamakeUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Moctar TounkaraUniversity Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.ORCID https://orcid.org/0000-0001-6443-8691
Shera WeyersClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of America.
Delgersaikhan ZulkhuuThe Liver Center, Onom Foundation, Ulan Bator, Mongolia.
Sally HunsbergerDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Renee RidzonDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID https://orcid.org/0000-0002-2822-8897
National Institutes of Health · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLLiberian Institute for Biomedical Research · LRNational Institute of Biomedical Research · CDFrederick National Laboratory for Cancer Research · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXRumah Sakit Umum Pusat Dr. Sardjito · ID

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

The International Study on COVID-19 Vaccines to Assess Immunogenicity, Reactogenicity, and Efficacy is an observational study to assess the immunogenicity of COVID-19 vaccines used in Democratic Republic of Congo, Guinea, Indonesia, Liberia, Mali, Mexico, and Mongolia. The study, which has enrolled 5,401 adults, is prospectively following participants for approximately two years. This study is important as it has enrolled participants from resource-limited settings that have largely been excluded from COVID-19 research studies during the pandemic. There are significant challenges to mounting a study during an international health emergency, especially in resource-limited settings. Here we focus on challenges and hurdles encountered during the planning and implementation of the study with regard to study logistics, national vaccine policies, pandemic-induced and supply chain constraints, and cultural beliefs. We also highlight the successful mitigation of these challenges through the team's proactive thinking, collaborative approach, and innovative solutions. This study serves as an example of how established programs in resource-limited settings can be leveraged to contribute to biomedical research during a pandemic response. Lessons learned from this study can be applied to other studies mounted to respond rapidly during a global health crisis and will contribute to capacity for stronger pandemic preparedness in the future when there is a crucial need for urgent response and data collection.

Identifiers

PMID37339111
PMCPMC10281570
OpenAlexW4381332211

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.